ZA200807721B - Anti-cancer pharmaceutical composition - Google Patents

Anti-cancer pharmaceutical composition

Info

Publication number
ZA200807721B
ZA200807721B ZA200807721A ZA200807721A ZA200807721B ZA 200807721 B ZA200807721 B ZA 200807721B ZA 200807721 A ZA200807721 A ZA 200807721A ZA 200807721 A ZA200807721 A ZA 200807721A ZA 200807721 B ZA200807721 B ZA 200807721B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
cancer pharmaceutical
cancer
composition
pharmaceutical
Prior art date
Application number
ZA200807721A
Other languages
English (en)
Inventor
Kosaku Fujiwara
Naomi Shimazaki
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of ZA200807721B publication Critical patent/ZA200807721B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ZA200807721A 2006-02-09 2008-09-08 Anti-cancer pharmaceutical composition ZA200807721B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006031791 2006-02-09

Publications (1)

Publication Number Publication Date
ZA200807721B true ZA200807721B (en) 2010-02-24

Family

ID=38345216

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200807721A ZA200807721B (en) 2006-02-09 2008-09-08 Anti-cancer pharmaceutical composition

Country Status (15)

Country Link
US (4) US8263631B2 (ru)
EP (1) EP1982718A4 (ru)
JP (2) JP5133071B2 (ru)
KR (1) KR20080101888A (ru)
CN (1) CN101415422B (ru)
AU (1) AU2007213028C1 (ru)
BR (1) BRPI0707671A2 (ru)
CA (1) CA2642665C (ru)
IL (1) IL193243A0 (ru)
NO (1) NO20083822L (ru)
NZ (1) NZ570381A (ru)
RU (1) RU2419430C2 (ru)
TW (1) TW200800181A (ru)
WO (1) WO2007091622A1 (ru)
ZA (1) ZA200807721B (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2007091622A1 (ja) 2006-02-09 2007-08-16 Daiichi Sankyo Company, Limited 抗癌医薬組成物
TW200838512A (en) * 2007-02-08 2008-10-01 Daiichi Sankyo Co Ltd Crystalline forms of a thiazolidinedione compound and manufacturing methods thereof
BRPI0809643A2 (pt) * 2007-04-05 2014-11-11 Daiichi Sankyo Co Ltd Derivados de heteroarila bicíclica fundida
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
RU2445366C2 (ru) 2007-09-28 2012-03-20 Чугаи Сейяку Кабусики Кайся Антитело против глипикана-3 с улучшенными кинетическими показателями в плазме
CL2009000647A1 (es) * 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
EP2311834A4 (en) 2008-07-31 2011-11-02 Daiichi Sankyo Co Ltd CRYSTAL OF A THIAZOLIDINE CONNECTION AND METHOD FOR THE PRODUCTION THEREOF
JPWO2010013768A1 (ja) * 2008-07-31 2012-01-12 第一三共株式会社 チアゾリジンジオン化合物の結晶及びその製造方法
DK2331136T3 (en) 2008-09-26 2018-03-05 Oncomed Pharm Inc FRIZZLED BINDING AGENTS AND APPLICATIONS THEREOF
WO2010070379A1 (en) * 2008-12-17 2010-06-24 Centre National De La Recherche Scientifique Rxr-ppargamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer
RU2480463C1 (ru) 2009-03-05 2013-04-27 Дайити Санкио Компани, Лимитед Пиридилокси производные, полезные в качестве активатора/модулятора гамма-рецептора, активируемого пролифератором пероксисом (ppar) гамма
CA2781800A1 (en) 2009-11-26 2011-06-03 Daiichi Sankyo Company, Limited Method for manufacturing a 6-substituted 1-methyl-1h-benzimidazole derivative and an intermediate of said method
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
WO2013086260A2 (en) * 2011-12-09 2013-06-13 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of cancer
RU2660354C2 (ru) 2012-04-03 2018-07-05 Новартис Аг Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
WO2014121036A1 (en) * 2013-02-01 2014-08-07 Deuterx, Llc 5-deutero-2,4-thiazolidinedione and 5-deutero-2,4-oxazolidinedione derivatives and compositions comprising and methods of using the same
CA2899353A1 (en) 2013-02-04 2014-08-07 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
JP6800013B2 (ja) 2013-03-14 2020-12-16 ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ 重水素化２，４−チアゾリジンジオン及び治療方法
WO2014145068A1 (en) * 2013-03-15 2014-09-18 Aerpio Therapeutics Inc. Compositions, formulations and methods for treating ocular diseases
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
EP3094328B1 (en) 2014-01-15 2020-08-19 Poxel SA Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
JP2016062874A (ja) * 2014-09-22 2016-04-25 株式会社ジャパンディスプレイ 画像表示装置及びその製造方法、並びに画像表示装置の検査方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3440134A4 (en) * 2016-04-04 2019-11-27 The Regents of the University of California LLS COMPOUNDS FOR THE TREATMENT OF CANCER
US10588880B2 (en) * 2016-09-28 2020-03-17 Eiger Biopharmaceuticals, Inc. Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
RU2692129C1 (ru) * 2018-03-19 2019-06-21 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ прогнозирования лимфогенного метастазирования у больных при аденокарциноме прямой кишки
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
CN113262306A (zh) * 2021-07-21 2021-08-17 北京大学第三医院（北京大学第三临床医学院） Pparg拮抗剂在肿瘤治疗药物中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228193B1 (en) * 1997-10-08 2013-01-28 Sankyo Co Imidazole fused heterocyclic compounds, process for their preparation, pharmaceutical compositions containing the same and their use
JP3488099B2 (ja) * 1997-10-08 2004-01-19 三共株式会社 置換縮合複素環化合物
GB9925958D0 (en) 1999-11-02 1999-12-29 Bundred Nigel J Therapeutic use
GB0017635D0 (en) * 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
DE10133394A1 (de) 2001-07-13 2003-01-30 Merck Patent Gmbh Flüssige Formulierung enthaltend Cetuximab
JP2003137814A (ja) * 2001-08-10 2003-05-14 Takeda Chem Ind Ltd ＧｎＲＨアゴニストの併用剤
JP2003192592A (ja) * 2001-10-17 2003-07-09 Sankyo Co Ltd 医薬組成物
WO2003032988A1 (fr) * 2001-10-17 2003-04-24 Sankyo Company, Limited Composition pharmaceutique
IL161462A0 (en) 2001-10-25 2004-09-27 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor
TW200300677A (en) * 2001-12-11 2003-06-16 Sankyo Co A pharmaceutical composition
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
IL164302A0 (en) 2002-03-29 2005-12-18 Chiron Corp Substituted benzazoles and use thereof as raf kinase inhibitors
WO2003082865A1 (fr) 2002-04-01 2003-10-09 Sankyo Company, Limited Composition médicinale antitumorale
JP2004083558A (ja) 2002-04-01 2004-03-18 Sankyo Co Ltd 抗腫瘍医薬組成物
CA2486215A1 (en) * 2002-06-14 2003-12-24 Merck & Co., Inc. Mitotic kinesin inhibitors
TW200403055A (en) * 2002-06-25 2004-03-01 Sankyo Co Pharmaceutical composition of a peroxisome proliferator-activated receptor (PPAR) gamma atcivetor and a diuretic
JP2004083574A (ja) * 2002-06-25 2004-03-18 Sankyo Co Ltd 利尿剤及びペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤を含有する医薬組成物
JP2005162727A (ja) * 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP2004315404A (ja) * 2003-04-15 2004-11-11 Sankyo Co Ltd ベンゾイミダゾール誘導体を含有する医薬
WO2005046665A1 (en) * 2003-11-13 2005-05-26 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and a erbb1/2 receptor inhibitor
CN1960730A (zh) * 2004-06-03 2007-05-09 霍夫曼-拉罗奇有限公司 用伊立替康(cpt－11)和egfr－抑制剂治疗
WO2007091622A1 (ja) 2006-02-09 2007-08-16 Daiichi Sankyo Company, Limited 抗癌医薬組成物

Also Published As

Publication number Publication date
IL193243A0 (en) 2009-02-11
CA2642665A1 (en) 2007-08-16
BRPI0707671A2 (pt) 2011-05-10
CN101415422B (zh) 2012-11-07
AU2007213028B2 (en) 2010-10-28
NO20083822L (no) 2008-11-05
US20090028868A1 (en) 2009-01-29
US20130183297A1 (en) 2013-07-18
CA2642665C (en) 2013-01-08
US20120263716A1 (en) 2012-10-18
US8263631B2 (en) 2012-09-11
TW200800181A (en) 2008-01-01
JP2012255042A (ja) 2012-12-27
CN101415422A (zh) 2009-04-22
EP1982718A1 (en) 2008-10-22
WO2007091622A1 (ja) 2007-08-16
RU2008136188A (ru) 2010-03-20
AU2007213028A1 (en) 2007-08-16
NZ570381A (en) 2011-02-25
EP1982718A4 (en) 2010-05-12
KR20080101888A (ko) 2008-11-21
JP5133071B2 (ja) 2013-01-30
RU2419430C2 (ru) 2011-05-27
JPWO2007091622A1 (ja) 2009-07-02
AU2007213028C1 (en) 2011-05-19
US20120258991A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
HUS1800007I1 (hu) Gyógyászati készítmény
ZA200807721B (en) Anti-cancer pharmaceutical composition
EP2001498A4 (en) PHARMACEUTICAL COMPOSITIONS
IL194176A0 (en) Pharmaceutical compositions
GB0713625D0 (en) Pharmaceutical compositions
EP2133095A4 (en) PHARMACEUTICAL COMPOSITION
EP2133094A4 (en) PHARMACEUTICAL COMPOSITION
EP2191826A4 (en) PHARMACEUTICAL COMPOSITION
HK1138732A1 (en) Pharmaceutical compositions
IL200125A0 (en) Pharmaceutical composition
EP2224805A4 (en) PHARMACEUTICAL COMPOSITION
EP2224915A4 (en) PHARMACEUTICAL COMPOSITIONS
HK1138774A1 (en) Pharmaceutical composition
EP2224808A4 (en) PHARMACEUTICAL COMPOSITION
EP2124959A4 (en) PHARMACEUTICAL COMPOSITION
EP2156832A4 (en) PHARMACEUTICAL COMPOSITION
EP2224806A4 (en) PHARMACEUTICAL COMPOSITION
IL205975A0 (en) Pharmaceutical composition
IL205931A0 (en) Pharmaceutical composition
GB0617578D0 (en) Pharmaceutical composition
GB0612696D0 (en) Pharmaceutical composition
GB0600032D0 (en) Pharmaceutical composition
GB0622964D0 (en) Pharmaceutical compositions
GB0609941D0 (en) Pharmaceutical compositions
ZA200808030B (en) Pharmaceutical compositions